Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Bryan Cho-Wing Li"'
Autor:
Vikki Tang, Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Bryan Cho Wing Li, Ka Wing Ma, Wong Hoi She, Chung Mau Lo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We ai
Externí odkaz:
https://doaj.org/article/5f87dbb432394523851e4b34b6953f4a
Autor:
Joanne Chiu, Polly S. Y. Cheung, Josephine Tsang, Roland Leung, Dacita Suen, Thomas Yau, Gerry Kwok, Ava Kwong, Bryan Cho Wing Li, T. T. Wong
Publikováno v:
Advances in Therapy. 38:5752-5762
Concurrent anthracycline and taxane is an effective and efficient way to deliver neoadjuvant chemotherapy for HER2-negative breast cancers. Data on efficacy and tolerance to 6 cycles of concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3ab79fa663e0f8cf6b92baf3b6c66fc
https://doi.org/10.1007/s12325-021-01933-1
https://doi.org/10.1007/s12325-021-01933-1
Autor:
Vikki Tang, Yu Cho Woo, David T W Lui, Alan Chun Hong Lee, Gerry Gin Wai Kwok, Tan To Cheung, R. Leung, Bryan Cho Wing Li, Karen S.L. Lam, Thomas Yau, Joanne Wing Yan Chiu, Chi Ho Lee, Carol H.Y. Fong
Publikováno v:
Endocrine Practice. 27:886-893
Objective Thyroid immune-related adverse events (irAEs) have been reported to have prognostic significance among patients with cancer treated with anti-programmed cell death-1 (PD1) and anti-programmed death-ligand 1 monotherapies. We evaluated the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e0da3c560fc929341a5f6e1ea1cbb1
https://doi.org/10.1016/j.eprac.2021.01.017
https://doi.org/10.1016/j.eprac.2021.01.017
Autor:
Thomas Yau, Vikki Tang, Wong Hoi She, Ka Wing Ma, Josephine Tsang, Gerry Gin Wai Kwok, Tan To Cheung, Albert C. Y. Chan, Bryan Cho Wing Li, Kit Shing, Joanne Chiu, Chung Mau Lo, Roland Leung
Publikováno v:
Advances in Therapy. 38:3900-3910
Treatment of hepatocellular carcinoma (HCC) recurrences following liver transplant (LT) is challenging. Most clinical trials of systemic therapies for advanced HCC excluded patients with any history of organ transplant. We aimed to assess the outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10268de0d1f45dfaeff136688f4b69a2
https://doi.org/10.1007/s12325-021-01800-z
https://doi.org/10.1007/s12325-021-01800-z
Autor:
Tracy Cy Shum, Yawen Dong, Thomas W. Leung, Wong Hoi She, Bryan Cho Wing Li, Vikki Tang, Cynthia S Y Yeung, Thomas Yau, Jeffrey Sum Lung Wong, Gerry Gin-Wai Kwok, Josephine Tsang, Ka Wing Ma, Ada Law, Anna Tai, Joanne Chiu, Tan To Cheung, Roland Leung
Publikováno v:
Cancers
Volume 13
Issue 9
Cancers, Vol 13, Iss 2002, p 2002 (2021)
Volume 13
Issue 9
Cancers, Vol 13, Iss 2002, p 2002 (2021)
Simple Summary The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ca9ffb8b43e9325dbc8cffb9d3bf489
http://europepmc.org/articles/PMC8122581
http://europepmc.org/articles/PMC8122581
Autor:
Roland Leung, Thomas Yau, Jeffrey Sum Lung Wong, Tan To Cheung, Joanne Chiu, Bryan Cho Wing Li, Josephine Tsang, Gerry Gin Wai Kwok
Publikováno v:
Expert review of gastroenterologyhepatology. 15(6)
The systemic treatment of advanced, unresectable hepatocellular carcinoma (HCC) has undergone an evolution in recent years. In March 2020, a combination of nivolumab and ipilimumab was approved by the FDA for treatment of patients with advanced HCC w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8060c9f5c9c8bf265e191c8b38684c8
https://pubmed.ncbi.nlm.nih.gov/33666530
https://pubmed.ncbi.nlm.nih.gov/33666530
Autor:
Alan C.H. Lee, Joanne W Y Chiu, R. Leung, Vikki Tang, Karen S.L. Lam, Chi Ho Lee, Tan To Cheung, Thomas Yau, Carol H.Y. Fong, Yu Cho Woo, Bryan Cho Wing Li, David T W Lui, Gerry G W Kwok
Publikováno v:
Journal of the Endocrine Society
Introduction: Thyroid immune-related adverse events (irAEs) have been reported to have prognostic significance among cancer patients treated with anti-PD1 and anti-PDL1 monotherapies. There are scanty data in the literature thus far about the clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9546c5f29bbfbf3c3bd9f4d3269564f
http://europepmc.org/articles/PMC8090404
http://europepmc.org/articles/PMC8090404
Autor:
Ryohichi Sugimura, Jeffrey Sum Lung Wong, Thomas Yau, Roland Leung, Joanne Wing Yan Chiu, Yawen Dong, Bryan Cho Wing Li, Tan To Cheung, Gerry Gin Wai Kwok, Ka-On Lam
Publikováno v:
Cancers, Vol 13, Iss 1949, p 1949 (2021)
Cancers
Cancers
Simple Summary Hepatocellular carcinoma is an aggressive cancer with high mortality. The introduction of immune-checkpoint inhibitors (ICIs) targeting the programmed-cell death 1 pathway (PD-1/L1) has led to a paradigmatic change in the systemic trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8118f0b8992e1f5792c547cd52cb31fd
https://doi.org/10.3390/cancers13081949
https://doi.org/10.3390/cancers13081949
Autor:
Joanne Chiu, Thomas Yau, Chung Mau Lo, Bryan Cho Wing Li, Jeffrey Sum Lung Wong, Ka Wing Ma, Josephine Tsang, Gerry Gin Wai Kwok, Tan To Cheung, Vikki Tang, Roland Leung, Wong Hoi She
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
BackgroundProgrammed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::627bcbe652eea3c3d5d4c78657177083
https://doi.org/10.1136/jitc-2020-001945
https://doi.org/10.1136/jitc-2020-001945
Autor:
Wong Hoi She, Ka Wing Ma, Thomas Yau, Gin Wai Kwok, Joanne Wing Yan Chiu, Bryan Cho Wing Li, Vikki Tang, Kit Shing, Tan To Cheung, Roland Leung
Publikováno v:
Journal of Clinical Oncology. 39:296-296
296 Background: Treatment of hepatocellular carcinoma (HCC) recurrences following liver transplant is challenging. All the clinical trials of systemic therapies for advanced HCC excluded patients with any history of organ transplant. Here we review o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1466e8f3c15b473f3db160a3f6a6fef8
https://doi.org/10.1200/jco.2021.39.3_suppl.296
https://doi.org/10.1200/jco.2021.39.3_suppl.296